Organon Laboratories

Organon is a global healthcare company dedicated to improving the health of women throughout their lives. Spun off from Merck & Co. in 2021, the company focuses on three core areas: Women's Health, Biosimilars, and Established Brands. Its portfolio includes more than 60 medicines and products, led by the long-acting reversible contraceptive Nexplanon and a robust biosimilars business in partnership with Samsung Bioepis. Organon is actively expanding its pipeline through strategic acquisitions and collaborations in areas such as endometriosis, preterm labor, and polycystic ovary syndrome. With a presence in over 140 markets, the company leverages its global commercial scale and manufacturing expertise to address significant unmet medical needs in female-centric healthcare.